SCHOTT Pharma is proud to celebrate its first anniversary as a listed company on the Frankfurt Stock Exchange. Since its successful IPO on September 28, 2023, the company has now completed a full financial year, continued to present strong financials and has made significant strides in its strategic initiatives.
“We can confidently say that our IPO was a tremendous success – for our shareholders, our customers, and our employees. In just one year, we have reached key milestones in the execution of our strategy. Our focus on innovation, expansion, and trustful relationships with customers and partners, will help us achieve our ambitious goals also in the future,” said Andreas Reisse, CEO of SCHOTT Pharma.
On 28 September 2023, SCHOTT Pharma CEO Andreas Reisse and CFO Dr. Almuth Steinkühler, surrounded by hundreds of cheering employees, rang in the new chapter of the company’s history on the trading floor of the Frankfurt Stock Exchange.
Just two months later, SCHOTT Pharma was admitted to the SDAX index, and in September 2024, climbed up the ranks to join the MDAX index. These achievements reflect the strong market confidence in SCHOTT Pharma’s growth trajectory and commitment to expansion and innovation and are testament to its attractive business model.
Over the past year, SCHOTT Pharma has initiated and progressed with ambitious projects to expand its network of production sites in Europe and the United States. These projects are set to enhance its global production footprint to meet the growing demand for innovative pharma drug containment solutions and delivery systems.
Innovation remains at the core of SCHOTT Pharma’s strategy. Since its IPO in September 2023, the company has launched several state-of-the-art products, including SCHOTT EVERIC® freeze, SCHOTT TOPPAC® Nest 160, as well as large volume cartriQ® ready-to-use (RTU) cartridges. These products underscore SCHOTT Pharma’s commitment to advancing solutions for the key trends in the healthcare industry.
“As we reflect on our achievements over the past year, we extend our gratitude to our internal team, our customers and partners, and shareholders for their unwavering support. We look forward to continuing our growth journey, driving value for all our stakeholders,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.